Adrian Valadez

Adrian Valadez

Auto-generated profile, based on publicly available information

Adrian Valadez

Department of Pharmacy Practice, Midwestern University, College of Pharmacy

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2026 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
AVAdrian Valadez
Adrian Valadez
MSMarc Scheetz
Marc Scheetz
MNMichael Neely
Michael Neely
HDHelen K. Donnelly
Helen K. Donnelly
EKErin Korth
Erin Korth
NRNathaniel Rhodes
Nathaniel Rhodes

2 June 2025 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
GRGriffin Reed
Griffin Reed
AVAdrian Valadez
Adrian Valadez
BSBrandon J. Smith
Brandon J. Smith
EMErin K. McCreary
Erin K. McCreary
EKEllen G. Kline
Ellen G. Kline
NRNathaniel Rhodes
Nathaniel Rhodes
Real-world meropenem-vaborbactam (MVB) pharmacokinetic-pharmacodynamic (PK/PD) attainment data in patients with renal dysfunction including continuous renal replacement (CRRT) are lacking. We evaluated MVB PK in patients with renal dysfunction and CRRT. Patients requiring hemodialysis were excluded. Plasma concentrations were quantified using LC-MS/MS. Multiple compartmental PK models and covariate effects were evaluated using Pmetrics 2.1.1. Free (f) fractions of 98% and 67% were assumed with targets of 40%– 100% f T >MIC and f AUC/MIC >38 for meropenem (MEM) and vaborbactam (VAB), respectively. Individual patient PK/PD attainment was evaluated using Bayesian posterior predictions. Probability of target attainment (PTA) stratified by MIC and cumulative fraction of response (CFR) vs the EUCAST K. pneumoniae distribution were evaluated for 2 and 4 g MVB regimens. Eighteen patients (54% female, 17% CRRT) aged 54 ± 14 years, weighing 91 ± 31 kg with a CrCL of 114 ± 102 mL/min/1.73 m 2 at baseline, contributed 83 plasma samples. For each drug, a one-compartment PK model was identified. Non-CRRT and residual clearance of MEM was higher than VAB, resulting in VAB accumulation. Individual-patient target attainment was variable. MEM PTA was >90% at MICs up to 0.5 mg/L, and VAB PTA was >90% at MICs up to 4 mg/L across renal states. CFR for MEM was >80%, and CFR for VAB was >70% in patients with renal dysfunction or CRRT and standard PK/PD targets with renal dosing regimens. For infections with MICs up to 1 mg/L, MVB regimens of 2 g IV every 8 h were adequate in CRRT. Studies linking MVB attainment to clinical outcomes are needed.

5 August 2026 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
AVAdrian Valadez
Adrian Valadez
EHEmma Harlan
Emma Harlan
CJColin Jeantet
Colin Jeantet
MSMarc Scheetz
Marc Scheetz
MNMichael Neely
Michael Neely
NRNathaniel Rhodes
Nathaniel Rhodes
Population pharmacokinetic (PK) models may not generalize across critically ill populations. We evaluated the transportability of published parametric and nonparametric meropenem models as Bayesian priors. Seven published meropenem models were implemented in Monolix 2024R1. Nonparametric models were converted to log-normal priors from reported medians and CV%. An independent cohort was used for evaluation. A priori and a posteriori predictions were summarized across eligible observations and separately for observations obtained during continuous renal replacement therapy (CRRT) and in the absence of CRRT. Predictive performance was assessed using relative mean prediction error (rMPE) and relative median absolute prediction error (rMdAPE). An rMPE within ±20% and an rMdAPE ≤30% were defined as acceptable. Seventeen patients, including six receiving CRRT, contributed 74 plasma concentrations. In the pooled cohort, only the Rohani and Shekar models met predefined performance thresholds at both population and individual levels ( a priori rMdAPE 24.6%–26.4%; a posteriori rMdAPE 6.7%–11.1%). In CRRT patients, no model achieved acceptable a priori performance; after Bayesian updating, all CRRT-specified models met accuracy and precision criteria, with the nonparametric models (Reed and Rohani) demonstrating low imprecision. In non-CRRT patients, several models showed population-level bias, but all met predefined accuracy and precision thresholds after Bayesian updating. Among evaluated models, Rohani, Reed, and Shekar demonstrated the most consistent predictive performance across the CRRT and non-CRRT subgroups. Nonparametric model summaries can be translated into parametric priors, but model selection remains critical when applying Bayesian dosing in critically ill patients.

10 December 2023 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
KPKrista Paplaczyk
Krista Paplaczyk
EWErin Weslander
Erin Weslander
AVAdrian Valadez
Adrian Valadez
CKChitaru Kurihara
Chitaru Kurihara
SGShannon R. Galvin
Shannon R. Galvin
NRNathaniel Rhodes
Nathaniel Rhodes

4 June 2025 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
AVAdrian Valadez
Adrian Valadez
MZMarta Zurawska
Marta Zurawska
EHEmma Harlan
Emma Harlan
MSMarc Scheetz
Marc Scheetz
MNMichael N. Neely
Michael N. Neely
NRNathaniel Rhodes
Nathaniel Rhodes
Cefepime (FEP) is used for hospital- and ventilator-associated pneumonia when Pseudomonas aeruginosa is involved. However, its pharmacokinetics (PK) in severe pneumonia necessitating extracorporeal membrane oxygenation (ECMO) remain unclear. This single-center, prospective study enrolled 70 mechanically ventilated patients with suspected pneumonia ( n = 9 on ECMO), excluding those on renal replacement therapy. Dosing followed institutional renal function-based protocols. Plasma concentrations were quantified by liquid chromatography-tandem mass spectrometry, and a two-compartment PK model was developed using Pmetrics for R, with volume of distribution (Vd) scaled to body weight and ECMO status, and clearance (CL) scaled to renal function. Target attainment was calculated from Bayesian posterior predictions, and Monte Carlo simulations evaluated the cumulative fraction of response (CFR) for regimens of 2 g IV every 8 h, administered as either 0.5 h intermittent or 4 h extended infusion with or without a 2 or 3 g loading dose (LD) (0.5 h). Success was defined as achieving 100% f T >1xMIC within 24 h for 80% of isolates. Seventy patients (60% male, n = 9 ECMO) contributed 114 plasma samples (1–14 per patient). The model fit the data well. ECMO was associated with a 2.8-fold increase in Vd without altering CL. Monte Carlo simulations demonstrated that standard dosing without an LD failed to achieve CFR ≥ 80% in ECMO patients. Incorporating a 3 g but not 2 g LD restored CFR to ≥80% in ECMO. ECMO significantly increased FEP Vd in intensive care unit patients, suggesting sub-optimal target attainment at higher minimum inhibitory concentrations. A 3 g LD appears essential for target attainment, underscoring the need for revised dosing strategies in ECMO.

4 February 2026 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
RWRyan Williamson
Ryan Williamson
MZMarta Zurawska
Marta Zurawska
AVAdrian Valadez
Adrian Valadez
EHEmma Harlan
Emma Harlan
MSMarc Scheetz
Marc Scheetz
NRNathaniel Rhodes
Nathaniel Rhodes
Optimizing antibiotic exposures in hospital-acquired pneumonia (HAP) is crucial; however, dosing decisions often overlook target levels for the beta-lactamase inhibitor tazobactam (TAZ), and the impact of renal dysfunction and renal replacement therapy on TAZ pharmacokinetics (PK) remains poorly described. We developed a population PK model of TAZ using 162 plasma samples from 35 ICU patients with HAP, including those receiving continuous renal replacement therapy (CRRT). TAZ concentrations were quantified using validated LC-MS/MS methods. A one-compartment model was fit using Monolix, with clearance modeled as a function of creatinine clearance, CRRT effluent flow rate, and intermittent hemodialysis. Monte Carlo simulations assessed the probability of unbound TAZ concentrations exceeding 1, 2, or 4 mg/L for 100% of the interval between 24 and 48 h across intermittent, extended, and continuous infusion (CI) regimens, stratified by renal function and CRRT. TAZ clearance was driven by renal function and CRRT flow rate. All regimens achieved ≥90% probability of target attainment (PTA) at thresholds of 1–2 mg/L. At 4 mg/L, PTA fell below 90% in patients with creatinine clearance ≥150 mL/min for all regimens, with low-dose CI performing the worst. High-dose CI improved PTA at this higher threshold but may increase the risk of piperacillin overexposure. TAZ exposures sufficient for enzymatic beta-lactamase inhibition are generally achieved with standard dosing for lower thresholds but not for more aggressive targets (e.g., high extended-spectrum β-lactamase expression), particularly in patients with preserved or augmented renal function, who may require therapeutic drug monitoring or alternative therapy.